Skip to main content

Table 1 Patient characteristics at inclusion

From: Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial

 

Total N = 21

Group - 1: alphacalcidol first N = 11

Group - 2: sevelamer carbonate first N = 10

p-value

Age (years)

65.6 ± 12.2

65.7 ± 9.6

65.5 ± 15.1

0.98a

Sex (males, females)

14 - 7

7 - 4

7 - 3

0.76b

Body mass index (kg/m2)

26.4 ± 3.4

25.8 ± 4.0

27.1 ± 2.7

0.40a

SBP (mmHg)

132 (115–194)

132 (115–194)

133 (123–167)

0.89c

DBP (mmHg)

84 (76–114)

85 (78–114)

84 (76–99)

0.57c

Creatinine (ÎĽmol/l)

154.4 ± 25.5

149.9 ± 27.7

159.4 ± 23.3

0.41a

eGFR (ml/min/1.73 m2)

36.6 ± 5.6

37.6 ± 6.5

35.6 ± 4.6

0.44a

Albumin/creatinin ratio (mg/mmol)d

1.4 (0.2-95.0)

1.7 (0.2-95.0)

1.1 (0.3-32.0)

0.83c

  1. Mean ± SD for normally distributed data, otherwise median and range.
  2. at-test for normally distributed variables.
  3. bchi-squared test for categorical variables.
  4. cMann-Whitney U-testing of non-parametric continuous variables.
  5. dmeasured at study end.